JP2020512308A - 細菌性感染症の患者を保護および治療するのに有用な、殺菌特性または静菌特性を有する細胞外基質組成物 - Google Patents
細菌性感染症の患者を保護および治療するのに有用な、殺菌特性または静菌特性を有する細胞外基質組成物 Download PDFInfo
- Publication number
- JP2020512308A JP2020512308A JP2019547408A JP2019547408A JP2020512308A JP 2020512308 A JP2020512308 A JP 2020512308A JP 2019547408 A JP2019547408 A JP 2019547408A JP 2019547408 A JP2019547408 A JP 2019547408A JP 2020512308 A JP2020512308 A JP 2020512308A
- Authority
- JP
- Japan
- Prior art keywords
- ubm
- extracellular matrix
- bacterial
- mrsa
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims abstract description 36
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims abstract description 36
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 36
- 210000002744 extracellular matrix Anatomy 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 208000035143 Bacterial infection Diseases 0.000 title abstract description 40
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract description 40
- 230000003385 bacteriostatic effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 40
- 239000011159 matrix material Substances 0.000 claims abstract description 17
- 210000000981 epithelium Anatomy 0.000 claims abstract description 14
- 210000004072 lung Anatomy 0.000 claims description 76
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 44
- 230000001580 bacterial effect Effects 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 35
- 241000894006 Bacteria Species 0.000 claims description 34
- 208000015181 infectious disease Diseases 0.000 claims description 26
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 16
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 14
- 241000191967 Staphylococcus aureus Species 0.000 claims description 10
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 9
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 9
- 210000002469 basement membrane Anatomy 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 7
- 210000002345 respiratory system Anatomy 0.000 claims description 6
- 210000004876 tela submucosa Anatomy 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 4
- -1 inhalation Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 210000003437 trachea Anatomy 0.000 claims description 3
- 239000008366 buffered solution Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 15
- 238000010586 diagram Methods 0.000 abstract description 13
- 238000009472 formulation Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 90
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 49
- 239000002953 phosphate buffered saline Substances 0.000 description 49
- 241000699666 Mus <mouse, genus> Species 0.000 description 38
- 238000001727 in vivo Methods 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 19
- 102000004127 Cytokines Human genes 0.000 description 18
- 108090000695 Cytokines Proteins 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 16
- 206010035664 Pneumonia Diseases 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 230000003214 anti-biofilm Effects 0.000 description 11
- 230000032770 biofilm formation Effects 0.000 description 11
- 108010012236 Chemokines Proteins 0.000 description 10
- 241000192125 Firmicutes Species 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102000019034 Chemokines Human genes 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 210000002919 epithelial cell Anatomy 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000000241 respiratory effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 101150093802 CXCL1 gene Proteins 0.000 description 5
- 206010011409 Cross infection Diseases 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 208000032536 Pseudomonas Infections Diseases 0.000 description 5
- 206010061924 Pulmonary toxicity Diseases 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 231100000374 pneumotoxicity Toxicity 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 101150031350 Cxcl2 gene Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000013691 Interleukin-17 Human genes 0.000 description 4
- 108050003558 Interleukin-17 Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- POFWRMVFWIJXHP-UHFFFAOYSA-N n-benzyl-9-(oxan-2-yl)purin-6-amine Chemical compound C=1C=CC=CC=1CNC(C=1N=C2)=NC=NC=1N2C1CCCCO1 POFWRMVFWIJXHP-UHFFFAOYSA-N 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 3
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 3
- 101150102665 CCL20 gene Proteins 0.000 description 3
- 101150077124 CXCL10 gene Proteins 0.000 description 3
- 101150102927 Cxcl3 gene Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 208000004852 Lung Injury Diseases 0.000 description 3
- 208000032376 Lung infection Diseases 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 101000685667 Mus musculus Bile acyl-CoA synthetase Proteins 0.000 description 3
- 101000715642 Mus musculus Bile salt-activated lipase Proteins 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010069363 Traumatic lung injury Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 231100000515 lung injury Toxicity 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 description 2
- 108700012434 CCL3 Proteins 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 102000000013 Chemokine CCL3 Human genes 0.000 description 2
- 208000025962 Crush injury Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 101150108366 Foxj1 gene Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000010065 bacterial adhesion Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000007047 pulmonary toxicity Effects 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 2
- 229950004616 tribromoethanol Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- 101150097262 Cxcl5 gene Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100031083 Uteroglobin Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000018290 type IV pilus-dependent motility Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
[0002] 本出願は、2017年3月31日に出願された米国仮特許出願第62/479,888号の優先権および利益を主張し、その全体が、すべての意図および目的のために参照により本明細書に組み込まれる。
UBM消化物の調製
マウスおよび畜産
細菌
肺毒性
マウスの細菌へのin vivo曝露
CFUアッセイ
BALFおよび細胞の百分率数
リアルタイムPCR分析
サイトカインアッセイ
肺組織病理学
バイオフィルムアッセイ
データ分析
結果
In vitro研究
UBMはin vitro抗菌活性を示す。
In vivo研究−UBMに対する組織の耐性
UBMは、肺において、十分な耐性があり、肺毒性を示さない。
In vivoUBM抗菌研究
UBMは、呼吸器感染症のマウスモデルにおいて、MSSAに対するin vivo抗菌活性を表す。
UBMは、MRSA誘発性呼吸器感染症からマウスを効果的に保護する
UBMの生物活性により、in vivoでの細菌の付着が防止される。
UBMは、緑膿菌誘発性呼吸器感染症からマウスを保護する
予め製剤化したUBMは、再構成後に抗菌活性を維持する。
予め製剤化した未消化のUBMにより、高用量の細菌誘発性呼吸器感染に対する保護効果が現れる。
結論
Claims (19)
- 患者において呼吸器感染症を治療するための方法であって、
失活した天然細胞外基質材料から得られ、有効用量の、未消化であり、非架橋の微粉化粉末を、気道を介して前記患者に投与することを含み、前記失活した天然細胞外基質(ECM)が、非上皮組織、膀胱基質(UBM)、小腸粘膜下組織(SIS)、および膀胱粘膜下組織(UBS)からなる群から選択される、方法。 - 前記微粉化粉末が、非酵素的に処理される、請求項1に記載の方法。
- 前記微粉化粉末が、室温で少なくとも2ヶ月間貯蔵される、請求項1に記載の方法。
- 前記微粉化粉末が、室温で少なくとも6ヶ月間貯蔵される、請求項1に記載の方法。
- 前記感染症が、黄色ブドウ球菌、緑膿菌、および肺炎桿菌からなる細菌の群から選択される、請求項1に記載の方法。
- 前記感染症が、少なくとも肺に局在している、請求項1に記載の方法。
- 前記気道が気管である、請求項1に記載の方法。
- 前記投与経路が気管内または鼻腔内である、請求項1に記載の方法。
- 前記投与経路が吸入によるものである、請求項1に記載の方法。
- 前記投与がスプレーを介するものである、請求項1に記載の方法。
- 前記細胞外基質材料が、膀胱基質(UBM)を含む、請求項1に記載の方法。
- 前記細胞外基質材料が、UBSを含む、請求項1に記載の方法。
- 前記治療が、前記患者の前記気道を緩衝溶液中の前記微粉化粒子で洗浄することを含む、請求項1に記載の方法。
- 上皮基底膜を含む失活した細胞外基質材料から得られる、未消化であり、非架橋の微粉化粉末を含む緩衝液中の再構成材料を含む組成物であって、前記再構成材料が、前記細胞外基質の1つ以上の天然成分を含む、組成物。
- 前記1つ以上の天然成分が、非上皮由来ECM、膀胱基質(UBM)、小腸粘膜下組織(SIS)、および膀胱粘膜下組織(UBS)からなる群から選択される、請求項14に記載の組成物。
- 細菌に感染した患者において、細菌性バイオフィルムの形成を減少させるための方法であって、
未消化であり、非架橋の、微粉化され、失活した上皮基底膜の細胞外基質を前記患者に投与することを含み、前記上皮基底膜がMSSA−黄色ブドウ球菌、MRSA−黄色ブドウ球菌、肺炎桿菌および緑膿菌からなる群から選択される1つ以上の細菌に対する殺菌活性を含む、方法。 - 前記失活した天然の細胞外基質(ECM)が、非上皮組織、UBM、SISおよびUBSからなる群から選択される、請求項16に記載の方法。
- 哺乳動物を細菌誘発性感染症から保護するための方法であって、
緩衝液中の、上皮基底膜の失活した細胞外基質材料から得た、未消化であり、非架橋の微粉化粉末を含む再構成材料を提供すること(ここで、前記再構成材料は、前記細胞外基質の1つ以上の天然成分を含む)、および
気管内注入、鼻腔内注入、吸入、スプレー、局所適用、およびこれらの組み合わせからなる群から選択される経路により、治療有効用量の前記物質を投与すること、
を含む、方法。 - 前記失活した細胞外基質(ECM)が、非上皮組織、UBM、SISおよびUBSからなる群から選択される、請求項18に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762479888P | 2017-03-31 | 2017-03-31 | |
US62/479,888 | 2017-03-31 | ||
PCT/US2018/024313 WO2018183181A1 (en) | 2017-03-31 | 2018-03-26 | Extracellular matrix compositions with bactericidal or bacteriostatic characteristics useful for protecting and treating patients with bacterial infections |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020512308A true JP2020512308A (ja) | 2020-04-23 |
Family
ID=61972242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019547408A Pending JP2020512308A (ja) | 2017-03-31 | 2018-03-26 | 細菌性感染症の患者を保護および治療するのに有用な、殺菌特性または静菌特性を有する細胞外基質組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20180280574A1 (ja) |
EP (1) | EP3600358A1 (ja) |
JP (1) | JP2020512308A (ja) |
KR (1) | KR102335573B1 (ja) |
CN (1) | CN110461343A (ja) |
AU (1) | AU2018244275B2 (ja) |
CA (1) | CA3058155C (ja) |
WO (1) | WO2018183181A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102335573B1 (ko) * | 2017-03-31 | 2021-12-06 | 아셀, 인크. | 세균 감염 환자를 보호 및 치료하는데 유용한 살균성 또는 정균성 특성을 갖는 세포외기질 조성물 |
US11788155B1 (en) * | 2019-06-06 | 2023-10-17 | University Of South Florida | Lung microbiome isolation and cultivation |
US11826490B1 (en) | 2020-12-29 | 2023-11-28 | Acell, Inc. | Extracellular matrix sheet devices with improved mechanical properties and method of making |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110262498A1 (en) * | 2008-12-05 | 2011-10-27 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Biologic Scaffold for Prevention of Pulmonary Fibrosis |
WO2014124203A1 (en) * | 2013-02-08 | 2014-08-14 | Acell, Inc. | Methods of manufacturing bioactive gels from extracellular matrix material |
JP2015510883A (ja) * | 2012-03-05 | 2015-04-13 | ユニバーシティ オブ メリーランド,ボルチモア | 多価ワクチンによる黄色ブドウ球菌感染症からの保護 |
JP2017504586A (ja) * | 2013-12-13 | 2017-02-09 | ユニバーシティー オブ ロチェスター | ブドウ球菌感染に対する受動免疫 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
KR102335573B1 (ko) * | 2017-03-31 | 2021-12-06 | 아셀, 인크. | 세균 감염 환자를 보호 및 치료하는데 유용한 살균성 또는 정균성 특성을 갖는 세포외기질 조성물 |
-
2018
- 2018-03-26 KR KR1020197031601A patent/KR102335573B1/ko active IP Right Grant
- 2018-03-26 US US15/935,707 patent/US20180280574A1/en not_active Abandoned
- 2018-03-26 CA CA3058155A patent/CA3058155C/en active Active
- 2018-03-26 JP JP2019547408A patent/JP2020512308A/ja active Pending
- 2018-03-26 EP EP18717798.5A patent/EP3600358A1/en not_active Withdrawn
- 2018-03-26 AU AU2018244275A patent/AU2018244275B2/en active Active
- 2018-03-26 CN CN201880021087.7A patent/CN110461343A/zh active Pending
- 2018-03-26 WO PCT/US2018/024313 patent/WO2018183181A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110262498A1 (en) * | 2008-12-05 | 2011-10-27 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Biologic Scaffold for Prevention of Pulmonary Fibrosis |
JP2015510883A (ja) * | 2012-03-05 | 2015-04-13 | ユニバーシティ オブ メリーランド,ボルチモア | 多価ワクチンによる黄色ブドウ球菌感染症からの保護 |
WO2014124203A1 (en) * | 2013-02-08 | 2014-08-14 | Acell, Inc. | Methods of manufacturing bioactive gels from extracellular matrix material |
JP2017504586A (ja) * | 2013-12-13 | 2017-02-09 | ユニバーシティー オブ ロチェスター | ブドウ球菌感染に対する受動免疫 |
Non-Patent Citations (1)
Title |
---|
TISSUE ENG, vol. 12, no. 10, JPN6020040410, 2006, pages 2949 - 2955, ISSN: 0005033558 * |
Also Published As
Publication number | Publication date |
---|---|
KR20190127935A (ko) | 2019-11-13 |
EP3600358A1 (en) | 2020-02-05 |
WO2018183181A1 (en) | 2018-10-04 |
AU2018244275B2 (en) | 2021-01-28 |
US20180280574A1 (en) | 2018-10-04 |
CA3058155A1 (en) | 2018-10-04 |
KR102335573B1 (ko) | 2021-12-06 |
CA3058155C (en) | 2023-09-26 |
CN110461343A (zh) | 2019-11-15 |
AU2018244275A1 (en) | 2019-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220362352A1 (en) | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby | |
Gawande et al. | Antibiofilm and antimicrobial efficacy of DispersinB®-KSL-W peptide-based wound gel against chronic wound infection associated bacteria | |
Choi et al. | Synergistic effect of antimicrobial peptide arenicin-1 in combination with antibiotics against pathogenic bacteria | |
Blanchette et al. | Current therapies in treatment and prevention of fracture wound biofilms: why a multifaceted approach is essential for resolving persistent infections | |
KR102335573B1 (ko) | 세균 감염 환자를 보호 및 치료하는데 유용한 살균성 또는 정균성 특성을 갖는 세포외기질 조성물 | |
US20040192581A1 (en) | Topical anti-infective formulations | |
EP3755363B9 (en) | Plantaricin nc8alphabeta variants | |
CA2759874C (en) | Methods of treating a pulmonary bacterial infection using fluoroquinolones | |
Miyake et al. | Future topical medications in chronic rhinosinusitis | |
Santoro et al. | Evaluation on the effects of 0.1% Peumus boldus leaf and Spiraea ulmaria plant extract combination on bacterial colonization in canine atopic dermatitis: A preliminary randomized, placebo controlled, double-blinded study | |
JP2023507201A (ja) | トロンビン由来ペプチドを含む組成物およびその使用 | |
JP2021510369A (ja) | 肺気腫及びその他の形態のcopdの治療のための組成物及び方法 | |
Chen et al. | Urinary bladder matrix protects host in a murine model of bacterial-induced lung infection | |
EP4208443A1 (en) | Hdac inhibitors for idiopathic pulmonary fibrosis and other lung inflammatory disorders | |
Balzli et al. | The effectiveness of an improved combination therapy for experimental Staphylococcus aureus keratitis | |
TWI610682B (zh) | 用於促進傷口癒合的吳郭魚抗菌胜肽 | |
Dal Monte et al. | Dexamethasone improves ofloxacin efficacy in treating acute bacterial conjunctivitis: Evidence from A rabbit model | |
KR102503309B1 (ko) | 동애등애 유충 추출물에서 분리된 펩타이드를 포함하는 항균용 조성물 | |
Kerget et al. | Evaluation of the Roflumilast Effect Supplemented with Linezolid in Pleural Empyema in Rats Caused by Intrapleural Staphylococcus aureus Inoculation | |
TWI578994B (zh) | 燒燙傷口癒合組合物 | |
KR20220099305A (ko) | P5 펩타이드를 포함하는 염증성 호흡기 질환 예방 또는 치료용 약학 조성물 | |
Kumar et al. | A combination of thalidomide and augmentin protects BALB/c mice suffering from Klebsiella pneumoniae B5055-induced sepsis | |
Damodaran et al. | Inhalational therapies for non-cystic fibrosis bronchiectasis | |
Kumar et al. | Clinical Management of Keratoconjunctivitis in Buffaloes-A Prospective Cohort Study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201022 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210420 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210420 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220328 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221209 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20221209 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20230105 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230216 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230217 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230414 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20230418 |